Incanthera (AQSE:INC) Equity-to-Asset : -4.14 (As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Incanthera Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Incanthera's Total Stockholders Equity for the quarter that ended in Sep. 2023 was £-0.67 Mil. Incanthera's Total Assets for the quarter that ended in Sep. 2023 was £0.16 Mil.

The historical rank and industry rank for Incanthera's Equity-to-Asset or its related term are showing as below:

AQSE:INC' s Equity-to-Asset Range Over the Past 10 Years
Min: -4.14 Med: 0.81 Max: 0.91
Current: -4.14

During the past 4 years, the highest Equity to Asset Ratio of Incanthera was 0.91. The lowest was -4.14. And the median was 0.81.

AQSE:INC's Equity-to-Asset is ranked worse than
96.34% of 1559 companies
in the Biotechnology industry
Industry Median: 0.67 vs AQSE:INC: -4.14

Incanthera Equity-to-Asset Historical Data

The historical data trend for Incanthera's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incanthera Equity-to-Asset Chart

Incanthera Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Equity-to-Asset

0.87

0.91

0.81

-1.09

Incanthera Semi-Annual Data
	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Equity-to-Asset	Get a 7-Day Free Trial			0.83	0.81	0.68	-1.09	-4.14

Competitive Comparison of Incanthera's Equity-to-Asset

For the Biotechnology subindustry, Incanthera's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Incanthera's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Incanthera's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Incanthera's Equity-to-Asset falls into.

Incanthera Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Incanthera's Equity to Asset Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Equity to Asset (A: Mar. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	-0.214	/	0.197
	=

Incanthera's Equity to Asset Ratio for the quarter that ended in Sep. 2023 is calculated as

Equity to Asset (Q: Sep. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	-0.667	/	0.161
	=

Incanthera (AQSE:INC) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Incanthera Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Incanthera's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Incanthera (AQSE:INC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incanthera PLC (AQSE:INC) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

76 King Street, Manchester, GBR, M2 4NH

Website

http://www.incanthera.com

Incanthera PLC is a specialist dermatology and oncology company focused on transforming cancer treatment by creating environments in which cancer cannot survive. It identifies and develops solutions to current clinical, commercially relevant unmet needs, utilising a new technology. The company's current products are Sol, EP0015, Equin and Duo-C. The company has one segment, namely the development of pharmaceutical products all within the United Kingdom.

Incanthera (AQSE:INC) Headlines

No Headlines